Terms ending in 2035
Every in-force patent on Ono Pharmaceutical Co., Ltd.'s record whose computed term ends in 2035, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,416,131 | Prophylactic Agent And/Or Therapeutic Agent for Diffuse Large B-Cell Lymphoma In force · High confidence | Ono Pharmaceutical Co., Ltd. | In force | High confidence | |
| US 10,137,129 | Prophylactic Agent And/Or Therapeutic Agent for Diffuse Large B-Cell Lymphoma In force · High confidence | Ono Pharmaceutical Co., Ltd. | In force | High confidence | |
| US 10,426,778 | Prophylactic Agent And/Or Therapeutic Agent for Diffuse Large B-Cell Lymphoma In force · High confidence | Ono Pharmaceutical Co., Ltd. | In force | High confidence | |
| US 10,407,426 | Dihydroindolizinone Derivative In force · High confidence | Ono Pharmaceutical Co., Ltd. | In force | High confidence | |
| US 10,550,119 | Dihydroindolizinone Derivative In force · High confidence | Ono Pharmaceutical Co., Ltd. | In force | High confidence | |
| US 10,815,233 | Dihydroindolizinone Derivative In force · High confidence | Ono Pharmaceutical Co., Ltd. | In force | High confidence | |
| US 10,208,034 | Quinoline Derivative In force · High confidence | Ono Pharmaceutical Co., Ltd. | In force | High confidence |
7 of 7 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.